Novo Nordisk’s semaglutide cuts death risk in diabetics with CKD in Phase III trial
Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly reduce the risk of death by 20% in diabetes patients with chronic kidney disease.